REFERENCES

General section

Bierley, J. D. et al. 2018. *TNM klasifikace zhoubných novotvarů*. 8. vyd. Praha: ÚZIS.

Büchler, T. et al. 2019. *Obecná onkologie*. Praha: Maxdorf.

Büchler, T. et al. 2023. *Speciální onkologie*. Praha: Maxdorf.

Klener, P., Klener, P. jr. 2010. *Nová protinádorová léčiva a léčebné strategie v onkologii*. Praha: Grada.

MZ ČR. 2025. *Screeningové programy*. Národní zdravotnický informační portál (online). https://www.nzip.cz/clanek/310-screeningove-programy

National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology, version 2. 2024.

Soumarová, R. et al. 2019. *Onkologie*. 2. vyd. Praha: Radioterapeutická a onkologická klinika 3. LF UK a FNKV (online). https://www.lf3.cuni.cz.

Šlampa, P. et al. 2021. *Radiační onkologie*. Praha: Maxdorf.

Vokurka, S. et al. 2018. *Onkologie v kostce*. Praha: Current Media.

Special section

Ambrosini, V. et al. 2021. Consensus on Molecular Imaging and Theranostics in Neuroendocrine Neoplasms. *European Journal of Cancer* 146: 56–73.

Aupérin, A. 2020. Epidemiology of Head and Neck Cancers: An Update. *Current Opinion in Oncology* 32 (3): 178–186.

Basuroy, R. et al. 2018. Delays and Routes to Diagnosis of Neuroendocrine Tumours. *BMC Cancer* 18: 1122.

Büchler, T. et al. 2017. *Speciální onkologie*. Praha: Maxdorf.

Caplin, M. E., Ratnayake, G. M. 2021. Diagnostic and Therapeutic Advances in Neuroendocrine Tumours. *Nature Reviews Endocrinology* 17 (2): 81–82.

Cervantes, A. et al. 2023. Metastatic Colorectal Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-up. *Annals of Oncology* 34 (1): 10–32.

Cibula, D. et al. 2023. ESGO/ESTRO/ESP Guidelines for the Management of Patients with Cervical Cancer – Update 2023. *International Journal of Gynecological Cancer* 33 (5): 649–666.

Cives, M., Strosberg, J. R. 2018. Gastroenteropancreatic Neuroendocrine Tumors. *CA: A Cancer Journal for Clinicians* 68 (6): 471–487.

Concin, N. et al. 2021. ESGO/ESTRO/ESP Guidelines for the Management of Patients with Endometrial Carcinoma. *International Journal of Gynecological Cancer* 31 (1): 12–39.

Conroy, T. et al. 2023. Pancreatic Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-up. *Annals of Oncology* 34 (11): 987–1002

Cornford, P. et al. 2024. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer – 2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. *European Urology* 86 (2): 148–163.

Falconi, M. et al. 2016. ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-functional Pancreatic Neuroendocrine Tumors. *Neuroendocrinology* 103: 153–171.

FDA. 2020. Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers (online). https: //www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug -interactions-table-substrates-inhibitors-and-inducers.

Foretová, L. et al. 2022. *Hereditární nádorová onemocnění v klinické praxi*. Praha: Grada.

Gondi, V. et al. 2022. Radiation Therapy for Brain Metastases: An ASTRO Clinical Practice Guideline. *Practical Radiation Oncology* 12 (4): 265–282.

Grégoire, V. et al. 2010. Squamous Cell Carcinoma of the Head and Neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology* 21 (Suppl. 5): 184–186.

Gronchi, A. et al. 2021. Soft Tissue and Visceral Sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. *Annals of Oncology* 32 (11): 1348–1365.

Klöppel, G. 2017. Neuroendocrine Neoplasms: Dichotomy, Origin and Classifications. *Visceral Medicine* 33 (5): 324–330.

van Leeuwen, R. W. F. et al. 2022. Evidence- and Consensus-based Guidelines for Drug-drug Interactions with Anticancer Drugs: A Practical and Universal Tool for Management. *Seminars in Oncology* 49 (2): 119–129.

Loibl, S. et al. 2024. Early Breast Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-up. *Annals of Oncology* 35 (2): 159–182.

Lordick, F. et al. 2022. Gastric Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-up. *Annals of Oncology* 33 (10): 1005–1020.

Mead, G. M., Stenning, S. P. 1997. The International Germ Cell Consensus Classification: A New Prognostic Factor-based Staging Classification for Metastatic Germ Cell Tumours. *Clinical Oncology* 9 (4): 207–209.

Michalets, E. 1998. Update: Clinically Significant Cytochrome P-450 Drug Interactions. *Pharmacotherapy* 18 (1): 84–112.

Modrá kniha České onkologické společnosti. 2024 (30. aktualizace).

National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology, version 2. 2024.

Obermannová, R. et al. 2022. Oesophageal Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-up. *Annals of Oncology* 33 (10): 992–1004.

Oldenburg, J. et al. Testicular Seminoma and Non-seminoma: ESMO-EURACAN Clinical Practice Guideline for Diagnosis, Treatment and Follow-up. *Annals of Oncology* 33 (4): 362–375.

Panzuto, F. et al. 2023. European Neuroendocrine Tumor Society (ENETS) 2023 Guidance Paper for Gastroduodenal Neuroendocrine Tumours (NETs) G1–G3. *Journal of Neuroendocrinology* 35 (8): e13306.

Pavel, M. et al. 2020. Gastroenteropancreatic Neuroendocrine Neoplasms: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. *Annals of Oncology* 31 (7): 844–860.

Powles, T. et al.2024. Renal Cell Carcinoma: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-up. *Annals of Oncology* 35 (8): 692–706.

Protokol pro léčbu CNS metastáz solidních nádorů. 2024. Komplexní onkologické centrum FN HK (online). https://www.fnhk.cz/fs4282/03.-metastazy-cns-2024.pdf.

Rao, S. et al. 2021. Anal Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. *Annals of Oncology* 32 (9): 1087–1100.

Remon, J. et al. 2021. Early and Locally Advanced Non-small-cell Lung Cancer (NSCLC): ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. *Annals of Oncology* 32 (12): 1637–1642.

Riechelmann, R. P., Del Gillio, A. 2009. Drug interactions in oncology: how common are they? *Annals of Oncology* 20: 1907–1912.

Le Rhun, E. et al. 2021. EANO-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up of Patients with Brain Metastasis from Solid Tumours. *Annals of Oncology* 32 (11): 1332–1347.

Seth, R. et al. 2023. Systemic Therapy for Melanoma: ASCO Guideline Update. *Journal of Clinical Oncology* 41 (30): 4794–4820.

Skřičková, J., Kadlec, B. 2014. Příznaky a rizika karcinomu plic. *Medicína pro praxi* 11 (1): 30–33.

Soumarová, R. et al. 2009. *Možnosti moderní radioterapie sarkomů měkkých tkání a kostí*. In 33. brněnské onkologické dny a 23. konference pro sestry a laboranty. https://www.linkos.cz.

Soumarová, R. 2021. *Radioterapie v léčbě nemelanomových kožních nádorů*. Praha: 3. LF UK.

Soumarová, R. et al. 2019. The Current Role of Radiotherapy and Systemic Therapy in the Multidisciplinary Treatment of Cholangiocarcinoma. *Časopis lékařů českých* 158 (2): 78–82.

Soumarová, R. et al. 2019. *Onkologie*. 2. vyd. Praha: Radioterapeutická a onkologická klinika 3. LF UK a FNKV (online). https://www.lf3.cuni.cz.

Suchopár, J. et al. 2023. *Lékové interakce: Obecné aspekty lékových interakcí*. Praha: DrugAgency.

Systém pro vizualizaci onkologických dat (online). www.svod.cz.

Tilki, D. et al. 2024. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II – 2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer. *European Urology* 86 (2): 164–182.

Vergote, I. et al. 2022. Clinical Research in Ovarian Cancer: Consensus Recommendations from the Gynecologic Cancer InterGroup. *The Lancet Oncology* 23 (8): e374–e384.

Vogel, A. et al. 2023. Biliary Tract Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-up. *Annals of Oncology* 34 (2): 127–140.

Vogelbaum, M. A. et al. Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline. *Journal of Clinical Oncology* 40 (5): 492–516.

Voll, M. L. et al. 2010. Petential Drug-drug Interactions between Anti-cancer Agents and Community Pharmacy Dispensed Drugs. *Pharmacy, World and Science* 32: 575–580.

Witjes, J. A. et al. 2024. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines. *European Urology* 85 (1): 17–31.

Zikán, M. et al. 2024. *Onkogynekologie*. Praha: Maxdorf.